New environment-friendly shield could offer better protection during dental surgery17 January 2022Dental patients and practitioners could be better protected from COVID-19 and other airborne viruses and bacteria thanks to the development of a new environment-friendly shield by a multidisciplinary team from the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (UHBW). The shield could also increase the number of patients seen by dentists and help reduce procedure wait times.
Bristol’s pioneering COVID-19 research prompts French Embassy visit10 December 2021Representatives from the French Embassy visited University labs today [10 December] to see some of the innovative COVID-19 research being undertaken at Bristol, including work on ADDomer™, a thermostable vaccine platform being developed by Bristol scientists to combat emerging infectious diseases.
Early warning signals could help monitor disease outbreaks
8 December 2021New research suggests early warning signals (EWSs) could help in the monitoring of disease outbreaks, such as COVID-19. The study, led by the University of Bristol, found warnings could be detected weeks earlier than any rapid increase in cases. The findings could help governments and policy makers improve the accuracy of their decisions and allow timely interventions if needed.
Child deaths during pandemic lowest on record for England7 December 2021The number of children in England who died fell to 3,067 between April 2020 – March 2021. This is 356 fewer deaths than were recorded in the preceding 12 months (April 2019 – March 2020), and likely represents the lowest level of child mortality on record, according to a new study by researchers at the Universities of Bristol and Cardiff and published today [7 December] in Archives of Disease in Childhood.
COVID-19 studies should record women’s menstrual changes, recommend researchers2 December 2021Large scale COVID-19 studies and clinical trials should collect data on menstrual changes, according to new research which evaluated current evidence. The findings, published in the International Journal of Epidemiology and led by University of Bristol researchers, say there is an important public health imperative for accurate scientific investigation of menstrual changes in relation to the COVID-19 pandemic.
School staff not at higher risk of death from COVID-19 than other occupations, study finds24 November 2021Primary and secondary school staff were not at greater risk of death from COVID-19 in 2020 compared to other professions in England and Wales, new research has found. The study, by researchers at the University of Bristol, analysed data from the Office for National Statistics (ONS) national death register for school staff and working adults aged between 20- to 64-years-old.
Can portable air filters prevent respiratory infections and COVID-19 in care homes?21 October 2021A major new randomised controlled trial will investigate the effectiveness of air filtration systems in preventing respiratory infections (such as coughs, colds and flu) and COVID-19 among care home residents in England. The AFRI-c (Air Filters to Prevent Respiratory Infections including COVID-19 in Care Homes) study, which received funding from the National Institute for Health Research (NIHR), is led by researchers at the University of Bristol.
Collaborative COVID-19 lockdown effort delivers major boost for vaccine innovation in Bristol 7 October 2021Faster vaccine development could be a step closer thanks to £4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer™. Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Race against the virus: the Oxford AstraZeneca COVID-19 vaccine journey28 September 2021In late December 2019, a cluster of unusual pneumonia cases - now known to be the first human cases of COVID-19 - were reported in Wuhan, China. Thanks to the quick action of an Oxford scientist and her team, work on the response to the new virus began. Members of the public have the opportunity to hear the story of the Oxford AstraZeneca COVID-19 vaccine at a free online event next month.
Major advance in race for SARS-CoV-2 inhibitor drugs20 September 2021A new advance towards the development of drugs specifically designed to inhibit a key SARS-CoV-2 enzyme is reported in the Royal Society of Chemistry's leading journal, Chemical Science. The international team, led by scientists from the Universities of Oxford and Bristol, has designed new peptide molecules and shown that they block (inhibit) the virus’s main protease [Mpro] - a prominent SARS-CoV-2 drug target.
SARS-CoV-2 transmission model suggests primary school infection could be greater this autumn than in 202013 September 2021The SARS-CoV-2 epidemic has already had a major impact on children's education, with schools having been required to implement infection control measures that have led to long periods of absence and classroom closures. With the new school year underway, risk modelling specialists at the University of Bristol have developed a new epidemiological model for SARS-CoV-2 transmission that forecasts primary school infection outbreaks could be more frequent and possibly substantially larger this autumn than in 2020, due to the more transmissive and infectious Delta variant and projected increase in community infection.
New option for how people with Covid-19 are cared for on NHS wards30 August 2021A new protocol for prone positioning — a technique commonly used to treat COVID-19 patients in respiratory distress by turning them on to their front to increase oxygen flow to the lungs, is published in the Journal of Frailty and Aging. Researchers from the University of Bristol in collaboration with clinicians at the Royal United Hospital in Bath, conducted a literature review of the manoeuvre to develop a standard protocol for the adjuvant treatment that can be used for COVID-19 patients at high risk of dying being treated in normal hospital wards.